Literature DB >> 1751146

Effect of recombinant human erythropoietin on vascular access.

G R Dy1, E J Bloom, G K Ijelu, G W Merritts, M S Kramer, R M Raja.   

Abstract

The use of recombinant human erythropoietin (r-HuEPO) corrects the anemia of chronic hemodialysis (HD) patients and improves their quality of life. The role of r-HuEPO in the genesis of graft thrombosis is controversial. A retrospective study was conducted of 46 stable chronic HD patients receiving r-HuEPO. It showed an increase in graft thrombosis in those who received the drug.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1751146

Source DB:  PubMed          Journal:  ASAIO Trans        ISSN： 0889-7190


  3 in total

1.  Dialysis access thrombosis in a family cohort.

Authors:  Arash Bornak; Lee Kirksey
Journal:  J Natl Med Assoc       Date:  2007-08       Impact factor: 1.798

2.  Thrombophilias and arteriovenous fistula dysfunction in maintenance hemodialysis.

Authors:  Ramazan Danis; Sehmus Ozmen; Davut Akin; Sabri Batun; Serdar Kahvecioglu; Abdullah Altintas; Mehmet E Yilmaz; Adil Polat
Journal:  J Thromb Thrombolysis       Date:  2008-03-25       Impact factor: 2.300

3.  rHuEPO hyporesponsiveness and related high dosages are associated with hyperviscosity in maintenance hemodialysis patients.

Authors:  Mehtap Erkmen Uyar; Selami Kocak Toprak; Hatice Saglam; Emre Tutal; Meltem Bay; Osman Ilhan; Zeynep Bal; Siren Sezer
Journal:  ScientificWorldJournal       Date:  2013-09-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.